News | April 10, 2013

CardioFocus Announces 1,000 HeartLight Cases Performed Worldwide

Company convened expert symposium in Boston to discuss clinical experiences


April 10, 2013 — CardioFocus Inc. announced that as of late 2012, more than 1,000 clinical cases have been performed worldwide using the HeartLight technology. The company hosted an expert symposium to review the clinical application of HeartLight and key observations made during the first 1,000 cases in January.

Prof. Karl-Heinz Kuck, M.D. of Asklepios Klinik St. Georg, Hamburg, Germany, and co-chair of the symposium, said, "Our clinical experience has demonstrated that the HeartLight technology possesses unique capabilities for the treatment of AF. Notably, it allows physicians the ability to directly see the tissue to be ablated, and offers a laser energy source to facilitate the creation of durable lesions irrespective of contact force. My colleagues and I have had the opportunity to evaluate its promising clinical impact, collect and analyze the data, and, now, further refine our technique to give patients the best chance of achieving freedom from AF."

Presentations focused on topics including techniques for utilizing the endoscopically-guided ablation system, the desired location of pulmonary vein isolation and the impact of HeartLight laser energy titration on achieving durable results. There was also a discussion of clinical results obtained using HeartLight in comparison to systems using alternative energy sources. In addition to Kuck, the event was co-chaired by Andrea Natale, M.D. of Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Austin, Texas, and Vivek Y. Reddy, M.D., of Mt. Sinai University Medical Center, New York, N.Y.

HeartLight is the first catheter ablation system to incorporate an endoscope, a laser energy source and a compliant balloon catheter to enable direct visualization of the beating heart during catheter ablation. The system is CE marked and clinically available in Europe and Australia. In the United States, it is investigational and currently the focus of an ongoing multi-center pivotal trial.

For more information, please visit

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init